Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from COSMO Pharmaceuticals N.V. ( (CH:COPN) ) is now available.
Cosmo Pharmaceuticals N.V. has announced the sale of its ‘Digital Trust’ division to Tinexta InfoCert for EUR 8.3 million as part of a strategic move to streamline its portfolio. This transaction aligns with Cosmo’s focus on growth in AI-powered medical devices and therapeutics, aiming to enhance its position as an innovation-driven healthcare company. By reallocating resources to core areas, Cosmo seeks sustainable growth and greater benefits for patients and shareholders.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF84.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a healthcare company focused on revolutionizing healthcare through innovative products that address unmet needs. Operating in Healthtech/AI, dermatology, gastroenterology, and contract manufacturing and development, Cosmo collaborates with global partners like Medtronic and Sun Pharma. Founded in 1997, the company is headquartered in Dublin, Ireland, with additional branches in the USA and Italy, employing approximately 330 people.
Average Trading Volume: 25,174
Current Market Cap: CHF948M
Learn more about COPN stock on TipRanks’ Stock Analysis page.